Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial. - Mujuru HA; White E; Kekitiinwa AR; Lugemwa A; Kityo C; Violari A; Ahimbisibwe GM; Variava E; Archary M; Cotton M; Ounchanum P; Puthanakit T; et al. (Open forum infectious diseases, 2026)